
Israel-based Oramed Pharmaceuticals, Inc. develops oral insulin capsules and drug delivery solutions.
Oramed Pharmaceuticals, Inc., founded in 2006 and headquartered in Jerusalem, is a biotech company specializing in the development of oral drug delivery systems. Their flagship product is an oral insulin capsule aimed at treating type 2 diabetes. The company also focuses on creating delivery solutions for other drugs and vaccines, striving to revolutionize the way medications are administered and improving patient compliance and outcomes.
Oramed has achieved significant milestones, including being publicly traded on Nasdaq (ORMP) and the Tel Aviv Stock Exchange (ORMP). The company is a component of the Russell Microcap Index. Notable achievements include a joint venture with HTIT to advance oral drug delivery technology globally and a distribution contract with Medicox for South Korea. CEO Nadav Kidron leads the company, which continues to make strides in the biotech industry.

Diasome Pharmaceuticals
diasome.com

Insulet
insulet.com

Htbt

Orcosa
orcosa.com

NovaDel Pharma

Concours Pharmaceuticals
Assertio Holdings

Oryza Pharmaceuticals
oryzapharma.com

OrphoMed

Galmed Pharmaceuticals
galmedpharma.com

i2o Therapeutics
i2obio.com

Generex Biotechnology
generex.com

Omeros
omeros.com

BioCryst Pharmaceuticals
biocryst.com

Orpro Therapeutics
Companies similar to Oramed Pharmaceuticals include Diasome Pharmaceuticals, Insulet, Htbt and Orcosa.
Oramed Pharmaceuticals was founded in 2006.
Oramed Pharmaceuticals' headquarters is located in New York City, NY, US.
Oramed Pharmaceuticals' most recent funding round was for $101.9M (USD) in September 2023.
As of Sep 21, 2023, Oramed Pharmaceuticals has raised a total of $236.6M (USD).
Oramed Pharmaceuticals has 13 employees as of Feb 6, 2024.